US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Birth Control

2,138.56

+3.690.17%

Number of Gainers:3

Number of Losers:2

Number of Flat:- -

PE:- -

High:2,184.15

Open:2,150.83

Low:2,129.92

Close:2,134.87

Volume:12.11M

Turnover:164.14M

Market Cap:34.35B

Float Cap:33.65B

Loading ...

Femasys Inc expected to post a loss of 9 cents a share - Earnings Preview

On National Viagra Day, Women Finally Claim Their Turn:

Enphase, AST SpaceMobile, AppLovin, ConocoPhillips, Teva Shock

Femasys Amends Financing Terms and Issues New Warrants

BRIEF-Femasys Enters Omnibus Amendment And Consent Agreement On March 19, 2026 - SEC Filing

Femasys Inc - Amendment Removes Share Combination Event Adjustment in Notes and Warrants Effective Dec 31, 2025 - SEC Filing

THOMSON REUTERS

Femasys issues 16,378,563 unregistered Series D-1 warrants at $0.58 exercise price

Daré Bioscience to Host Full Year 2025 Financial Results and Company Update Conference Call and Webcast on March 26, 2026

Top Teva Executive Makes Major Stock Move That Investors Can’t Ignore

Femasys appoints Kenneth D. Eichenbaum to board of directors

BRIEF-Femasys Appoints Dr. Kenneth D. Eichenbaum To Board Of Directors

Press Release: Femasys Appoints Dr. Kenneth D. Eichenbaum to Board of Directors

Femasys Appoints DR. Kenneth D. Eichenbaum to Board of Directors

THOMSON REUTERS

Daré Bioscience completes Regulation A sale of 43,050 investor units at USD 5 each

Dare Bioscience receives NIH funding award notice for DARE-PTB1

Daré Bioscience Receives NIH Funding Award Notice to Advance DARE-PTB1, its Novel Intravaginal Ring for Prevention of Preterm Birth

FDA clears Daré Bioscience IND for DARE-HPV Phase 2 study

Evofem Q4 net sales rose 35% to USD 9.6 million as net income totaled USD 2.8 million

Evofem Reports Fifth Consecutive Year of Net Sales Growth

THOMSON REUTERS

Femasys Inc. Publishes Corporate Presentation on Women’s Reproductive Health Devices

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BK4584/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4584","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4584\",,,,,undefined,":{"symbol":"BK4584","market":"US","secType":"PLATE","nameCN":"Birth Control","latestPrice":2138.5625,"timestamp":1774295999999,"preClose":2134.8713,"halted":0,"volume":12111670,"delay":0,"changeRate":0.001729,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Closed","change":3.691162,"latestTime":"03-23 16:00:00 EDT","open":2150.8262,"high":2184.1477,"low":2129.9165,"amount":164143670.489092,"amplitude":0.025403,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1774310400000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":4.447776,"peRate":25.857654,"turnoverRate":0.007971,"increases":3,"decrements":2,"flats":0,"marketCap":34353940654,"floatMarketCap":33652961166},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4584\",,,,,undefined,":{"symbol":"BK4584","high":2184.1477,"amplitude":0.025403,"preClose":2134.8713,"low":2129.9165,"pbRate":"4.447776","latestPrice":2138.5625,"volume":12111670,"delay":0,"open":2150.8262,"prevYearClose":2379.9924,"prevWeekClose":2134.8713,"prevMonthClose":2521.1123,"prevQuarterClose":2379.9924,"fiveDayClose":2196.147,"twentyDayClose":2570.1104,"sixtyDayClose":2409.9392,"secType":"PLATE","market":"US","turnoverRate":0.007971,"peRate":25.857654,"marketCap":34353940654,"floatMarketCap":33652961166,"timestamp":1774295999999,"nameCN":"Birth Control"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4584\",,,,undefined,":{"bkCode":"BK4584","up":3,"down":2,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4584\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2621208105","title":"Femasys Inc  expected to post a loss of 9 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2621208105","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621208105?lang=en_us&edition=fundamental","pubTime":"2026-03-24 04:13","pubTimestamp":1774296790,"startTime":"0","endTime":"0","summary":"Femasys Inc  expected to post a loss of9cents a share - Earnings Preview Femasys Inc FEMY.OQ FEMY.O is expected to  show a rise in quarterly revenue when it reports  results on March 25 (estimated) fo","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nL8N40B2BW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4584","FEMY","BK4082","BK4539"],"gpt_icon":0},{"id":"2621703368","title":"On National Viagra Day, Women Finally Claim Their Turn:","url":"https://stock-news.laohu8.com/highlight/detail?id=2621703368","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621703368?lang=en_us&edition=fundamental","pubTime":"2026-03-23 20:00","pubTimestamp":1774267200,"startTime":"0","endTime":"0","summary":"You Can Be Part of It.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/23/3260306/30757/en/On-National-Viagra-Day-Women-Finally-Claim-Their-Turn.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DARE","BK4584","BK4139","BK4585","LABU","BK4007","ACOG","NHLD","BK4588"],"gpt_icon":0},{"id":"2621760788","title":"Enphase, AST SpaceMobile, AppLovin, ConocoPhillips, Teva Shock","url":"https://stock-news.laohu8.com/highlight/detail?id=2621760788","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621760788?lang=en_us&edition=fundamental","pubTime":"2026-03-21 21:00","pubTimestamp":1774098044,"startTime":"0","endTime":"0","summary":"Insiders have been trading these 5 stocks: (($ENPH)), (($ASTS)), (($APP)), (($COP)) and (($TEVA)). Here is a breakdown of their recent trades and t...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/weekend-updates/enphase-ast-spacemobile-applovin-conocophillips-teva-shock?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/weekend-updates/enphase-ast-spacemobile-applovin-conocophillips-teva-shock?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0942090050.USD","LU0256331488.USD","LU2294711713.HKD","LU0456854461.SGD","LU0130103400.USD","LU0417517546.SGD","IE00BZ9MQY76.HKD","LU1201861249.SGD","LU0648001328.SGD","BK4539","LU0648000940.SGD","LU0314106906.USD","IE00B19Z9P08.USD","BK4213","LU0368265418.SGD","LU1506573853.SGD","IE00BGHQF524.EUR","LU1548497426.USD","LU2087625088.SGD","LU0122376428.USD","IE00B2Q91V27.USD","ASTS","IE00BN0W2T93.GBP","LU2360107168.USD","BK4566","LU0238689110.USD","LU2250418816.HKD","ENPH","LU0345781412.USD","LU2264538146.SGD","LU0353189680.USD","LU2357305700.SGD","LU0130102774.USD","LU0980610538.SGD","APPX","LU0345780950.USD","BK4147","LU0266512127.USD","LU2125154778.USD","BK4585","LU1201861165.SGD","LU2357125470.USD","LU0889566641.SGD","APP","LU0792757196.USD","LU0256863811.USD","LU2290526834.HKD","IE00B19Z9Z06.USD","LU1852331112.SGD","LU0868494617.USD","IE00BN0W2W23.USD","LU2360032135.SGD","LU0868494708.USD","BK4588","LU0130517989.USD","LU1988902786.USD","LU1861215975.USD","LU2506951792.HKD","LU2125154935.USD","LU0300736492.USD","LU0353189763.USD","BK4608","LU0097036916.USD","LU0788109394.HKD","LU0082616367.USD","LU0348723411.USD","BK4023","LU1983299162.USD","LU2324357040.USD","LU2360106780.USD","LU1267930813.SGD","LU0477156953.USD","IE00B3CCJ963.GBP","BK4613","LU0823414478.USD","BK4557","LU0823414551.USD","BK4570","BK4559","TEVA","LU1064131342.USD","LU1983299246.USD","IE00B894F039.SGD","LU0300736062.USD","LU0061474960.USD","LU1720051017.SGD","IE00BN0W2V16.EUR","LU1720051108.HKD","BK4007","LU2249611893.SGD","LU0957791311.USD","LU1815333072.USD","COP","LU0056508442.USD","LU0719512351.SGD","BK4584","LU2063271972.USD","LU1861220033.SGD","LU1074936037.SGD","LU0630314457.HKD","BK4596"],"gpt_icon":0},{"id":"2621269752","title":"Femasys Amends Financing Terms and Issues New Warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2621269752","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621269752?lang=en_us&edition=fundamental","pubTime":"2026-03-21 05:51","pubTimestamp":1774043489,"startTime":"0","endTime":"0","summary":"Femasys ( ($FEMY) ) just unveiled an update. Femasys Inc. amended its November 3, 2025 Securities Purchase Agreement with certain lenders on March ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/femasys-amends-financing-terms-and-issues-new-warrants?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/femasys-amends-financing-terms-and-issues-new-warrants?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4082","BK4539","FEMY","BK4584"],"gpt_icon":0},{"id":"2621752195","title":"BRIEF-Femasys Enters Omnibus Amendment And Consent Agreement On March 19, 2026 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2621752195","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621752195?lang=en_us&edition=fundamental","pubTime":"2026-03-21 05:43","pubTimestamp":1774043010,"startTime":"0","endTime":"0","summary":"BRIEF-Femasys Enters Omnibus Amendment And Consent Agreement On March 19, 2026 - SEC FilingMarch 20  - SEC Filing:FEMASYS INC - ENTERS OMNIBUS AMENDMENT AND CONSENT AGREEMENT ON MARCH 19, 2026 - SEC FILINGFEMASYS INC - AMENDMENT REMOVES SHARE COMBINATION EVENT ADJUSTMENT IN NOTES AND WARRANTS EFFECTIVE DEC 31, 2025 - SEC FILINGSource text: [ID:n0001140361-26-010591]Further company coverage: FEMY.O ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260320:nFWN4080TX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","BK4584","FEMY","BK4539"],"gpt_icon":0},{"id":"2621754016","title":"Femasys Inc - Amendment Removes Share Combination Event Adjustment in Notes and Warrants Effective Dec 31, 2025 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2621754016","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621754016?lang=en_us&edition=fundamental","pubTime":"2026-03-21 05:18","pubTimestamp":1774041492,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260320:nFWN4080TX:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["FEMY","BK4539","BK4584","BK4082"],"gpt_icon":0},{"id":"2621754019","title":"Femasys issues 16,378,563 unregistered Series D-1 warrants at $0.58 exercise price","url":"https://stock-news.laohu8.com/highlight/detail?id=2621754019","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621754019?lang=en_us&edition=fundamental","pubTime":"2026-03-21 05:17","pubTimestamp":1774041440,"startTime":"0","endTime":"0","summary":"Femasys entered an omnibus amendment and consent agreement with certain note and warrant holders to remove a share combination event adjustment, effective Dec. 31, 2025.In connection with the amendments, the company will issue 16,378,563 unregistered Series D-1 warrants with an exercise price of USD 0.58 per share.Each Series D-1 warrant entitles the holder to acquire common shares equal to the number of shares underlying that holder’s Series A-1 warrant.The warrants are being issued in reliance on the Securities Act Section 4 exemption to accredited investors.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Femasys Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, a","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260320:nNDL4qBf18:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","FEMY","BK4584","BK4539"],"gpt_icon":0},{"id":"2620735505","title":"Daré Bioscience to Host Full Year 2025 Financial Results and Company Update Conference Call and Webcast on March 26, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2620735505","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620735505?lang=en_us&edition=fundamental","pubTime":"2026-03-20 20:00","pubTimestamp":1774008000,"startTime":"0","endTime":"0","summary":"SAN DIEGO, March  20, 2026 (GLOBE NEWSWIRE) --  Dare Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising scie","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/20/3259697/30757/en/Dar%C3%A9-Bioscience-to-Host-Full-Year-2025-Financial-Results-and-Company-Update-Conference-Call-and-Webcast-on-March-26-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4181","BK4588","BK4218","BK4007","HST","BK4584","DARE","BK4585"],"gpt_icon":0},{"id":"2620206385","title":"Top Teva Executive Makes Major Stock Move That Investors Can’t Ignore","url":"https://stock-news.laohu8.com/highlight/detail?id=2620206385","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620206385?lang=en_us&edition=fundamental","pubTime":"2026-03-20 10:09","pubTimestamp":1773972593,"startTime":"0","endTime":"0","summary":"New insider activity at Teva Pharmaceutical ( ($TEVA) ) has taken place on March 19, 2026. Teva Pharmaceutical’s Executive Vice President for Inter...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/top-teva-executive-makes-major-stock-move-that-investors-cant-ignore-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/top-teva-executive-makes-major-stock-move-that-investors-cant-ignore-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ISBC","BK4559","TEVA","BK4566","BK4585","BK4557","BK4596","LU1983299246.USD","BK4588","BK4007","BK4584","LU2324357040.USD","BK4211"],"gpt_icon":0},{"id":"2620598942","title":"Femasys appoints Kenneth D. Eichenbaum to board of directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2620598942","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620598942?lang=en_us&edition=fundamental","pubTime":"2026-03-18 21:05","pubTimestamp":1773839116,"startTime":"0","endTime":"0","summary":"Femasys appointed Kenneth Eichenbaum to its board of directors. Eichenbaum is a board-certified anesthesiologist with clinical affiliations at Corewell Health William Beaumont University Hospital and Trinity Health Oakland Hospital. He has more than 20 years of experience evaluating biotechnology and medical device companies and advising investment firms. Femasys also noted that Joshua Silverman is no longer serving on the board.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL7LLB8Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2T93.GBP","IE00BN0W2W23.USD","BK4585","FEMY","IE00B3QW5Z07.USD","LU2210150020.SGD","IE00BGHQF748.EUR","BK4588","LU0314104364.USD","NDAQ","IE00BKPKM429.USD","SG9999014005.SGD","SG9999014013.SGD","BK4539","BK4082","LU2210149790.SGD","IE00B64PRP62.GBP","SG9999014021.USD","SG9999014039.USD","BK4584","BK4112","LU2095319765.USD","IE00BN0W2V16.EUR"],"gpt_icon":0},{"id":"2620256071","title":"BRIEF-Femasys Appoints Dr. Kenneth D. Eichenbaum To Board Of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2620256071","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620256071?lang=en_us&edition=fundamental","pubTime":"2026-03-18 21:04","pubTimestamp":1773839070,"startTime":"0","endTime":"0","summary":"BRIEF-Femasys Appoints Dr. Kenneth D. Eichenbaum To Board Of DirectorsMarch 18 (Reuters) - Femasys Inc FEMY.O:FEMASYS APPOINTS DR. KENNETH D. EICHENBAUM TO BOARD OF DIRECTORSSource text: ID:nGNX2XBwzkFurther company coverage: FEMY.O ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nTUABFFFFW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4584","FEMY","BK4082"],"gpt_icon":0},{"id":"2620256287","title":"Press Release: Femasys Appoints Dr. Kenneth D. Eichenbaum to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2620256287","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620256287?lang=en_us&edition=fundamental","pubTime":"2026-03-18 21:01","pubTimestamp":1773838860,"startTime":"0","endTime":"0","summary":"ATLANTA, March 18, 2026  -- Femasys Inc. , a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women worldwide, announced today the appointment of Kenneth D. Eichenbaum, M.D., M.S.E., to its Board of Directors. Dr. Eichenbaum is a board-certified anesthesiologist with clinical affiliations at Corewell Health William Beaumont University Hospital and Trinity Health Oakland Hospital, bringing deep clinical expertise and strategic insight developed through more than 20 years of evaluating biotechnology and medical device companies and advising investment firms. He completed a fellowship at Stanford University Medical Center and earned his M.D. from the Icahn School of Medicine at Mount Sinai, with additional degrees in engineering from the University of Pennsylvania and in finance from The Wharton School.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","R","BK4157","FEMY","ITI","BK4232","BK4022","BK4584","BK4539"],"gpt_icon":0},{"id":"2620725644","title":"Femasys Appoints DR. Kenneth D. Eichenbaum to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2620725644","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620725644?lang=en_us&edition=fundamental","pubTime":"2026-03-18 21:00","pubTimestamp":1773838805,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nTUABFFFFW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4082","BK4539","BK4584","FEMY"],"gpt_icon":0},{"id":"2620403678","title":"Daré Bioscience completes Regulation A sale of 43,050 investor units at USD 5 each","url":"https://stock-news.laohu8.com/highlight/detail?id=2620403678","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620403678?lang=en_us&edition=fundamental","pubTime":"2026-03-18 04:38","pubTimestamp":1773779929,"startTime":"0","endTime":"0","summary":"Daré Bioscience completed a closing of its previously announced Regulation A offering of up to 4,854,000 units priced at USD 5 per unit. The company issued 43,050 investor units consisting of 43,050 shares of Series A convertible preferred stock and warrants to purchase up to 86,100 common shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dare Bioscience Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 17, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nNDL2WSP82:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","DARE","BK4584"],"gpt_icon":0},{"id":"2619463832","title":"Dare Bioscience receives NIH funding award notice for DARE-PTB1","url":"https://stock-news.laohu8.com/highlight/detail?id=2619463832","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619463832?lang=en_us&edition=fundamental","pubTime":"2026-03-16 20:39","pubTimestamp":1773664791,"startTime":"0","endTime":"0","summary":"Dare Bioscience (DARE) announced receipt of a revised Notice of Award from the Eunice Kennedy Shriver National Institute of Child Health and Human ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/dare-bioscience-receives-nih-funding-award-notice-for-dare-ptb1-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/dare-bioscience-receives-nih-funding-award-notice-for-dare-ptb1-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4584","DARE"],"gpt_icon":0},{"id":"2619746347","title":"Daré Bioscience Receives NIH Funding Award Notice to Advance DARE-PTB1, its Novel Intravaginal Ring for Prevention of Preterm Birth","url":"https://stock-news.laohu8.com/highlight/detail?id=2619746347","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619746347?lang=en_us&edition=fundamental","pubTime":"2026-03-16 20:00","pubTimestamp":1773662400,"startTime":"0","endTime":"0","summary":" Extends the budget period for the ~$2M total NIH grant funding award for DARE-PTB1 through November 2026 DARE-PTB1 targets preterm birth, for which there are no FDA-approved treatment options Award r","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/16/3256190/30757/en/Dar%C3%A9-Bioscience-Receives-NIH-Funding-Award-Notice-to-Advance-DARE-PTB1-its-Novel-Intravaginal-Ring-for-Prevention-of-Preterm-Birth.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NICHD","BK4007","IVR","BK4584","DARE","BK4110","REI","BK4202","BK4213"],"gpt_icon":0},{"id":"2618131297","title":"FDA clears Daré Bioscience IND for DARE-HPV Phase 2 study","url":"https://stock-news.laohu8.com/highlight/detail?id=2618131297","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618131297?lang=en_us&edition=fundamental","pubTime":"2026-03-12 20:02","pubTimestamp":1773316970,"startTime":"0","endTime":"0","summary":"The FDA cleared Daré Bioscience’s investigational new drug  application for a planned Phase 2 clinical study of DARE-HPV. Sabrina Martucci Johnson discussed the IND clearance in a virtual investor segment, Virtual Investor “What This Means” segment. The company also cited non-dilutive funding support, including a contract for funding from ARPA-H.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260312:nNDL94yhCR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4584","SG9999014005.SGD","IE00B3QW5Z07.USD","LU2210150020.SGD","DARE","LU2210149790.SGD","IE00B64PRP62.GBP","SG9999014013.SGD","BK4588","SG9999014021.USD","SG9999014039.USD","IE00BKPKM429.USD","NDAQ","LU2095319765.USD","BK4007","BK4585","BK4112","LU0314104364.USD","IE00BGHQF748.EUR"],"gpt_icon":0},{"id":"2618910973","title":"Evofem Q4 net sales rose 35% to USD 9.6 million as net income totaled USD 2.8 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2618910973","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618910973?lang=en_us&edition=fundamental","pubTime":"2026-03-12 04:08","pubTimestamp":1773259706,"startTime":"0","endTime":"0","summary":"Evofem reported FY 2025 net sales of USD 20.2 million, up 4%, reflecting a higher PHEXX wholesale average cost and a slightly improved gross-to-net ratio, with SOLOSEC also contributing. FY 2025 operating income was USD 3.4 million, and net income attributable to common stockholders was USD 0.3 million, or USD 0.00 per basic and diluted share. Total operating expenses in FY 2025 fell 38% to USD 16.8 million, driven by a USD 5.6 million gain from settling a portion of trade payables and a USD 1.9 million non-cash gain tied to a change in accounting estimates on a contingent royalty liability. In Q4 2025, net sales rose 35% to USD 9.6 million, mainly reflecting higher PHEXX WAC, a more favorable gross-to-net ratio, and higher ex-factory unit sales. Q4 2025 net income was USD 2.8 million, or USD 0.02 per basic and USD 0.00 per diluted share.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nNDL7CtcMW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4584","BK4007","EVFM"],"gpt_icon":0},{"id":"2618297359","title":"Evofem Reports Fifth Consecutive Year of Net Sales Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2618297359","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618297359?lang=en_us&edition=fundamental","pubTime":"2026-03-12 04:05","pubTimestamp":1773259502,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nTUA9X1FWX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","EVFM","BK4584"],"gpt_icon":0},{"id":"2618095211","title":"Femasys Inc. Publishes Corporate Presentation on Women’s Reproductive Health Devices","url":"https://stock-news.laohu8.com/highlight/detail?id=2618095211","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618095211?lang=en_us&edition=fundamental","pubTime":"2026-03-11 00:09","pubTimestamp":1773158955,"startTime":"0","endTime":"0","summary":"Femasys released a corporate presentation outlining its portfolio in fertility, permanent birth control and other gynecology products, citing more than 200 issued global patents. The company highlighted FemaSeed intratubal insemination trial data showing a 26% pregnancy rate in women with male factor or unexplained infertility and a 18% per-cycle pregnancy rate. Femasys also described FemBloc as a non-surgical permanent birth control system approved in Europe, the UK and New Zealand, with an ongoing U.S. pivotal trial targeting a 1-year pregnancy-rate endpoint in 401 patients. The presentation cited a USD 20 billion total market and a USD 3 billion annual market opportunity for permanent birth control. It also referenced U.S. pricing ranges of USD 500 to USD 4,000 per IUI cycle and USD 30,000 for IVF.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated c","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260310:nNDL730kY9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4584","FEMY","BK4539","BK4082"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":24,"code":"91000000","status":"200"}]}}